Nutrition & Supplements

Glucosamine

An amino sugar naturally present in cartilage, used as an oral supplement to support joint health in dogs with osteoarthritis. Evidence for benefit is moderate; it is generally safe and widely used.

Glucosamine is an amino sugar (glucose + glutamine) and a precursor molecule for glycosaminoglycans — the proteoglycan chains that give articular cartilage its compressive resilience. As a supplement, it is proposed to provide substrate for cartilage repair and exert anti-inflammatory effects on chondrocytes.

Forms of Glucosamine

  • Glucosamine hydrochloride (HCl): most common veterinary form; 83% glucosamine by weight
  • Glucosamine sulfate: used in most human research; less studied in dogs
  • N-acetylglucosamine (NAG): different metabolism; less used in veterinary products

Evidence Base

The evidence for glucosamine in dogs is mixed but generally positive for early-stage osteoarthritis:

  • Multiple placebo-controlled trials show modest improvement in lameness and pain scores in dogs with OA
  • The benefit is more consistent in early-stage disease than advanced disease with significant cartilage loss
  • Onset of effect is slow (4–8 weeks) — insufficient duration of trial is a common cause of perceived ineffectiveness
  • Bioavailability studies show oral glucosamine reaches joint cartilage in dogs, addressing a historical concern

A 2007 Cochrane review of human evidence found glucosamine superior to placebo for OA but inferior to NSAIDs — likely applicable to dogs in relative terms.

Dosing

Standard veterinary dosing: 20–25 mg/kg/day, typically dosed once daily.

For a 30 kg dog: 600–750 mg glucosamine daily as a maintenance dose.

Safety

Glucosamine is extremely well tolerated in dogs. Reported adverse effects are rare and mild (GI upset at high doses). No significant drug interactions are established. It is safe for concurrent use with NSAIDs and other joint medications.

Combination with Chondroitin

Glucosamine is commonly formulated with chondroitin sulfate. The combination may have additive or synergistic effect — chondroitin inhibits cartilage-degrading enzymes (MMPs) while glucosamine provides biosynthetic substrate. The GAIT trial (human) found the combination superior to either alone in moderate-severe OA subgroups.